Michigan is currently home to 2237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Recruiting
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Spectrum Health Medical Group, Grand Rapids, Michigan
Conditions: Obstructive Hypertrophic Cardiomyopathy
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Recruiting
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/09/2025
Locations: Clinical Site, Waterford, Michigan
Conditions: Hidradenitis Suppurativa
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Recruiting
The objective of this study is to determine the safety, tolerability, and anti-leukemic activity of S227928 as single agent and in combination with venetoclax, and to determine the recommended Phase 2 dose (RP2D) of this combination. The study will begin as a Phase 1 Dose Escalation study to determine the RP2D and then will transition to a Phase 2 Dose Expansion study to assess the efficacy of the selected RP2D. During the treatment period participants will have study visits every two weeks, wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Recruiting
The goal of this study is to determine if rapid outpatient evaluation vs hospitalization management is the best strategy (based on patient-centered measures and safe, equitable, and efficient resource use) for evaluating patients with acute chest pain who are at moderate risk for acute coronary syndrome (ACS). Patients will be randomized in the Emergency Department to either an outpatient evaluation (CARE-CP) or hospitalization evaluation for their symptoms.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/09/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Chest Pain
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Alcohol Associated Hepatitis
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan
Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
Recruiting
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear \[209668: NCT04449029\], B-Together \[209348: NCT04676724\], B-F... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: GSK Investigational Site, Detroit, Michigan
Conditions: Hepatitis B
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Recruiting
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Karmanos Cancer Center, Detroit, Michigan
Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma
Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment
Recruiting
Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-ter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan
Conditions: Sleep Disordered Breathing, Able Bodied
Medtronic Cardiac Surgery PMCF Registry
Recruiting
This registry is being conducted to support ongoing post-market surveillance activities.
Gender:
ALL
Ages:
All
Trial Updated:
04/09/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Valve Disease, Heart
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Recruiting
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocar... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
Recruiting
This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used classes of cancer drugs. CIPN symptoms are typically minor at first but can progress with continued treatment to severe symptoms that can affect long-term function, falls risk, and quality of life. Sy... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/03/2025
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Breast Carcinoma